Skip to content
value.today

Acton Pharmaceuticals, Inc.

🇺🇸 Marlborough, Massachusetts, USAPharmaceuticalsFounded 2008
Total raised
$21 M
2 rounds on record
Latest round
$7 M
May 2013
First round on record
Sep 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Acton Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2013$7 MNo. 2$2 to $10 million

Acton Pharmaceuticals, Inc.: Raise no. 2, May 2013

Investors in this round

2 investors had bought by the notice of May 20, 2013: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
$295,406
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Kreisler · Executive Officer, Director, Promoter · President and Treasurer
  • John Simon · Executive Officer, Director, Promoter · Chief Executive Officer and Secretary
  • Thomas Phair · Executive Officer · Senior Vice President and Chief Financial Officer
  • Scott Carter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series A-2 Convertible Preferred Stock”

Signed by John Simon, Chief Executive Officer and Secretary. Source: SEC Form D, newest notice filed May 20, 2013. Read the notice at the SEC.

equitySEC
Sep 2010$14 MNo. 1$10 to $50 million

Acton Pharmaceuticals, Inc.: Raise no. 1, Sep 2010

Investors in this round

2 investors had bought by the notice of Sep 30, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
$590,794
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Kreisler · Executive Officer, Director · President and Treasurer
  • John Simon · Executive Officer, Director · Chief Executive Officer and Secretary
  • Scott Carter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series A-1 Convertible Preferred Stock”

Signed by John Simon, Chief Executive Officer and Secretary. Source: SEC Form D, newest notice filed Sep 30, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Acton Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2013).

    SEC Form D · May 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2013

That is all the official record says: Acton Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Acton Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Acton Pharmaceuticals, Inc.
NameRoleNamed in
Daniel KreislerPresident and TreasurerMay 2013
John SimonChief Executive Officer and SecretaryMay 2013
Thomas PhairSenior Vice President and Chief Financial OfficerMay 2013
Daniel KreislerPresident and TreasurerMay 2013
John SimonChief Executive Officer and SecretaryMay 2013
Scott CarterDirectorMay 2013
Daniel KreislerPresident and TreasurerMay 2013
John SimonChief Executive Officer and SecretaryMay 2013